Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06816251
PHASE2

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

Sponsor: Shandong Suncadia Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with non-obstructive hypertrophic cardiomyopathy.

Official title: A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2025-02-25

Completion Date

2025-08

Last Updated

2025-03-05

Healthy Volunteers

No

Interventions

DRUG

HRS-1893

HRS-1893 tablet.

DRUG

HRS-1893 placebo

HRS-1893 tablet placebo.

Locations (1)

Fuwai Hospital

Beijing, Beijing Municipality, China